Hellwig Stephan, Drossard Jürgen, Twyman Richard M, Fischer Rainer
Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Worringerweg 1, D-52074 Aachen, Germany.
Nat Biotechnol. 2004 Nov;22(11):1415-22. doi: 10.1038/nbt1027.
The use of whole plants for the synthesis of recombinant proteins has received a great deal of attention recently because of advantages in economy, scalability and safety compared with traditional microbial and mammalian production systems. However, production systems that use whole plants lack several of the intrinsic benefits of cultured cells, including the precise control over growth conditions, batch-to-batch product consistency, a high level of containment and the ability to produce recombinant proteins in compliance with good manufacturing practice. Plant cell cultures combine the merits of whole-plant systems with those of microbial and animal cell cultures, and already have an established track record for the production of valuable therapeutic secondary metabolites. Although no recombinant proteins have yet been produced commercially using plant cell cultures, there have been many proof-of-principle studies and several companies are investigating the commercial feasibility of such production systems.
与传统的微生物和哺乳动物生产系统相比，利用整株植物合成重组蛋白因其在经济性、可扩展性和安全性方面的优势，近来受到了广泛关注。然而，使用整株植物的生产系统缺乏培养细胞的一些内在优势，包括对生长条件的精确控制、批次间产品一致性、高度的封闭性以及按照良好生产规范生产重组蛋白的能力。植物细胞培养结合了整株植物系统以及微生物和动物细胞培养的优点，并且在生产有价值的治疗性次生代谢产物方面已有成功记录。尽管尚未使用植物细胞培养进行重组蛋白的商业生产，但已有许多原理验证研究，并且几家公司正在研究这种生产系统的商业可行性。
